Literature DB >> 1846776

Flow cytometric determination of breast tumor heterogeneity.

J E Fuhr1, A Frye, A A Kattine, S Van Meter.   

Abstract

Flow cytometric analysis was done on the DNA content of nuclei obtained from different sites of small breast tumors. Although specimens for analysis were obtained within a few millimeters of each other, dramatic differences were occasionally observed in the DNA histograms. In a limited study involving 141 consecutive breast specimens submitted for flow cytometry, 52% (74) were found to have at least one DNA aneuploid population. In 18% of DNA aneuploid tumors, one or more specimens from areas grossly identified as tumor had no DNA aneuploid population. Because of the proposed correlation of aneuploidy with a poorer prognosis and possible responsiveness to chemotherapy, multiple sites should be assayed when flow cytometric DNA analysis is done.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1846776     DOI: 10.1002/1097-0142(19910301)67:5<1401::aid-cncr2820670521>3.0.co;2-4

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  8 in total

1.  Genetic heterogeneity of primary and metastatic breast carcinoma defined by fluorescence in situ hybridization.

Authors:  J F Simpson; D E Quan; J P Ho; M L Slovak
Journal:  Am J Pathol       Date:  1996-09       Impact factor: 4.307

2.  Tumour heterogeneity of DNA cell cycle variables in breast cancer measured by flow cytometry.

Authors:  E Bergers; P J van Diest; J P Baak
Journal:  J Clin Pathol       Date:  1996-11       Impact factor: 3.411

3.  Advanced breast cancer treatment with folinic acid, 5-fluorouracil, and mitomycin C.

Authors:  G Francini; R Petrioli; A Aquino; S Gonnelli
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

4.  S-phase fraction identifies high-risk subgroups among DNA-diploid breast cancers.

Authors:  H Romero; J Schneider; J Burgos; J Bilbao; F J Rodriguez-Escudero
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

Review 5.  Alternative therapies for metastatic breast cancer: multimodal approach targeting tumor cell heterogeneity.

Authors:  Manpreet Sambi; Sabah Haq; Vanessa Samuel; Bessi Qorri; Fiona Haxho; Kelli Hill; William Harless; Myron R Szewczuk
Journal:  Breast Cancer (Dove Med Press)       Date:  2017-02-28

6.  Tumour growth rate and DNA flow cytometry parameters as prognostic factors in metastatic melanoma.

Authors:  T Muhonen; S Pyrhönen; A Laasonen; V M Wasenius; S Asko-Seljavaara; K Franssila; L Kangas
Journal:  Br J Cancer       Date:  1992-09       Impact factor: 7.640

7.  Lack of prognostic significance of DNA ploidy and S phase fraction in breast cancer.

Authors:  P D Stanton; T G Cooke; S J Oakes; J Winstanley; S Holt; W D George; G D Murray
Journal:  Br J Cancer       Date:  1992-11       Impact factor: 7.640

8.  Cytogenetic analysis of multifocal breast carcinomas: detection of karyotypically unrelated clones as well as clonal similarities between tumour foci.

Authors:  M R Teixeira; N Pandis; G Bardi; J A Andersen; N Mandahl; F Mitelman; S Heim
Journal:  Br J Cancer       Date:  1994-11       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.